When was Karius founded?

Karius was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is Karius located?

Karius is headquartered in Redwood City, United States. It is registered at Redwood City, California.

How many employees does Karius have?

As of Apr 30, 2026, the latest employee count at Karius is 205.

Is Karius a funded company?

Karius is a funded company, having raised a total of $315M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 20, 2016.

When was the latest funding round of Karius?

Karius' latest funding was a $***** Series C round on May 02, 2024, with participation from 10 investors. Its primary sector is Healthcare IT. In United States, the Healthcare IT sector has seen $3.19B in funding in 2026 to date.

Where does Karius rank among its competitors?

Karius ranks 11th amongst 421 active competitors, of which 101 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was HaystackAnalytics, which secured $5M in Sep, 2025.

Who are the top competitors of Karius?

Karius' top competitors include Adaptive Biotechnologies, MeMed and OpGen. Among them, HaystackAnalytics secured the most recent funding round in September, 2025.

Karius - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of diagnostics for identifying infectious diseases using microbial DNA. It offers Karius Test that uses clinical metagenomics specifically microbial cell-free DNA, or mcfDNA plus AI and sequencing to detect pathogens such as bacteria, fungi, viruses, parasites in the body from non-invasive samples.

Website: kariusdx.com
Social
Email ID: *****@kariusdx.com
Phone Number: +1 **********
Registered Address: Redwood City, California

Key Metrics

Founded Year

2014

Location

Redwood City, United States

Stage

Series C

Total Funding

$315M in 5 rounds

Latest Funding Round

Series C, May 02, 2024, $*****

Investors

Khosla Ventures & 17 more

Ranked

11^th among 421 active competitors

Employee Count

205 as on Apr 30, 2026

Similar Companies

Innovaccer & 2826 more

View Karius' full profile

Karius is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Karius, Inc. CIN: 471779950 , United States, Active	Aug 26, 2014	-	177 (As on Dec 31, 2024)	-

Karius has raised a total funding of $315M over 5 rounds. Its first funding round was on Sep 20, 2016. Its latest funding round was a Series C round on May 02, 2024 for $*****. 10 investors participated in its latest round. Karius has 18 institutional investors.

Here is the list of recent funding rounds of Karius:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 02, 2024	7994964	Series C	3765570	5762587	8290197	9710019
Feb 24, 2020	4602493	Series B	5227343	7995892	4201858	General Catalyst & 3 more
Nov 29, 2018	6513466	Conventional Debt	6807801	8021569	3858498	Oxford Finance

Access funding benchmarks and valuations. Sign up today!

View details of Karius's funding rounds and investors

The founders of Karius is Tim Blauwkamp. Alec Ford is the CEO of Karius.

Here are the details of Karius' key team members:

Tim Blauwkamp: Chief Scientific Officer, Co-founder of Karius.
Alec Ford: CEO of Karius.
Contact Info: 1 email address

View details of Karius's Founder profiles and Board Members

Karius' employee count trend

Karius has 205 employees as of Apr 26. Here is Karius's employee count trend over the years:

Uncover Karius' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Karius include Adaptive Biotechnologies, MeMed and OpGen. Here is the list of Top 10 competitors of Karius, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	77/100
2nd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
3rd	OpGen 2002, Rockville (United States), Public	Developer of diagnostics and bioinformatics platforms for providers	$77.5M	Cross Creek, 180 Degree Capital & 12 others	67/100
4th	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	SINE, STRIVE & 31 others	67/100
5th	Inflammatix 2016, San Francisco (United States), Series E	Provider of diagnostic solutions for systemic infections	$191M	Khosla Ventures, Think.Health & 16 others	64/100
6th	Day Zero Diagnostics 2016, Boston (United States), Series B	Developer of genome sequencing-based diagnostics for infectious diseases	$49M	Sands Capital, Triventures & 10 others	62/100
7th	NeuroKaire 2017, Kearny (United States), Series A	Platform offering personalized treatment for psychiatric and neurological conditions	$20M	GreyBird Ventures, Meron Capital & 6 others	62/100
8th	Sophia Genetics 2011, Rolle (Switzerland), Public	AI-driven platform for clinicians to generate real-time insights for patients with cancer and rare disorders	$249M	Generation Investment Management, Balderton Capital ... & 23 others	62/100
9th	Seegene Technologies 2000, Seoul (South Korea), Acquired	Developer of molecular diagnostic kits to detect infectious and genetic diseases	-	IMM Investment, Songhyun Investment & 3 others	59/100
10th	Oncimmune 2006, Nottingham (United Kingdom), Acquired	Immunodiagnostics company developing biomarker platforms for cancer and immune diseases	-	Balderton Capital, IPF Partners & 9 others	58/100
11th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	S28 Capital, Lightspeed Venture Partners ... & 16 others	58/100